Related Experiment Video

Updated: May 28, 2026

Use of a Central Venous Line for Fluids, Drugs and Nutrient Administration in a Mouse Model of Critical Illness
09:17

Use of a Central Venous Line for Fluids, Drugs and Nutrient Administration in a Mouse Model of Critical Illness

Published on: May 2, 2017

Mortality after fluid bolus in African children with sepsis

Benny L Joyner, Jenny M Boyd, Keith C Kocis

    The New England Journal of Medicine
    |October 14, 2011
    PubMed
    Abstract

    No abstract available in PubMed .

    Related Experiment Videos

    Last Updated: May 28, 2026

    Use of a Central Venous Line for Fluids, Drugs and Nutrient Administration in a Mouse Model of Critical Illness
    09:17

    Use of a Central Venous Line for Fluids, Drugs and Nutrient Administration in a Mouse Model of Critical Illness

    Published on: May 2, 2017

    Related Concept Videos

    Cholera01:25

    Cholera

    Cholera is an acute gastrointestinal disease caused by the Gram-negative bacterium Vibrio cholerae. It is transmitted primarily via the fecal-oral route through the ingestion of contaminated water or food.Vibrio cholerae is a motile, Gram-negative bacterium of the family Vibrionaceae, primarily associated with waterborne outbreaks in areas with inadequate sanitation. Although over 200 serogroups of V. cholerae exist, only O1 and O139 are responsible for epidemic cholera. The O1 serogroup,...
    Acute Kidney Injury III: Clinical Manifestations01:29

    Acute Kidney Injury III: Clinical Manifestations

    Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
    Pneumonia III: Complications and Assessment01:30

    Pneumonia III: Complications and Assessment

    Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

    Articles linked to this work by shared authors, journal, and citation graph.

    Part 1: Executive Summary: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.

    Circulation·2025

    Part 6: Pediatric Basic Life Support: 2025 American Heart Association and American Academy of Pediatrics Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.

    Circulation·2025

    Part 6: Pediatric Basic Life Support: 2025 American Heart Association and American Academy of Pediatrics Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.

    Pediatrics·2025

    The Frequency of Multiple Central Line-Associated Bloodstream Infections (CLABSIs) Occurring in the Same Child: A Five-Year Experience.

    Joint Commission journal on quality and patient safety·2025

    An Incognito Standardized Patient Approach for Measuring and Reducing Intersectional Healthcare Stigma: A Pilot Cluster Randomized Control Trial.

    Journal of acquired immune deficiency syndromes (1999)·2025

    An Incognito Standardized Patient Approach for Measuring and Reducing Intersectional Healthcare Stigma: A Pilot Cluster Randomized Control Trial.

    Journal of acquired immune deficiency syndromes (1999)·2025

    Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis.

    The New England journal of medicine·2026

    Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.

    The New England journal of medicine·2026

    Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk.

    The New England journal of medicine·2026

    Eplontersen for Transthyretin Amyloid Cardiomyopathy.

    The New England journal of medicine·2026

    Myeloproliferative Neoplasms.

    The New England journal of medicine·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us